SCHEMBL23958346

SCHEMBL23958346

Cc1ccccc1-n1c(Nc2cccnc2)nc2cc(F)ccc2c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE7A Q13946 1/20 0.46
ALDH1A1 P00352 3/20 0.45
LMNA P02545 2/20 0.45
KDM4E B2RXH2 2/20 0.45
MAPT P10636 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
MPI P34949 2/20 0.45
G6PD P11413 1/20 0.45
PKM P14618 1/20 0.45
HTT P42858 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
APOBEC3G Q9HC16 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.43
JUN P05412 1/20 0.42
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
TP53 P04637 1/20 0.41
IDO1 P14902 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23958208 0.92 TDO2 (0.48) PDE7AALDH1A1LMNAKDM4EMAPT
SCHEMBL30103275 0.92 TDO2 (0.48) PDE7AALDH1A1LMNAKDM4EMAPT
SCHEMBL24111074 0.86 ALOX12 (0.45) PDE7AMAPTKMT2AALOX12
SCHEMBL23958205 0.82 TDO2 (0.48) L3MBTL1IDO1GLAKMT2ATDO2
SCHEMBL30103212 0.82 TDO2 (0.48) L3MBTL1IDO1GLAKMT2ATDO2
SCHEMBL24110983 0.80 TDO2 (0.49) ALDH1A1LMNAKDM4EMAPTSMN1; SMN2
SCHEMBL29423292 0.80 TDO2 (0.49) ALDH1A1LMNAKDM4EMAPTSMN1; SMN2
SCHEMBL23958144 0.80 TP53 (0.44) PDE7AALDH1A1LMNASMN1; SMN2L3MBTL1
SCHEMBL23958344 0.80 PIK3CD (0.45) PDE7AALDH1A1LMNAL3MBTL1JUN
SCHEMBL23958283 0.80 HTR7 (0.46) LMNAMAPTL3MBTL1TP53TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210387967-A1 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-12-16 US disclosed
WO-2021215537-A1 2-HETEROARYLAMINOQUINAZOLINONE DERIVATIVE 大日本住友製薬株式会社 (JP) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210387967-A1 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE CRKL, CLIC4, CLIC1 PDE7A 3371/4885ALDH1A1 1803/4885LMNA 2210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.